X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (396) 396
male (311) 311
female (300) 300
cardiac & cardiovascular systems (291) 291
aged (263) 263
middle aged (244) 244
abridged index medicus (142) 142
treatment outcome (138) 138
mortality (135) 135
risk factors (128) 128
acute coronary syndromes (125) 125
heart attacks (125) 125
cardiovascular (89) 89
time factors (87) 87
double-blind method (86) 86
coronary heart disease (83) 83
care and treatment (81) 81
risk (80) 80
stroke (80) 80
aspirin (78) 78
cardiovascular disease (78) 78
myocardial-infarction (74) 74
myocardial infarction (71) 71
anticoagulants (70) 70
drug therapy (69) 69
myocardial infarction - mortality (68) 68
atrial fibrillation (67) 67
registries (67) 67
peripheral vascular disease (66) 66
rivaroxaban (66) 66
risk assessment (65) 65
prognosis (64) 64
acute myocardial-infarction (63) 63
electrocardiography (63) 63
medicine, general & internal (63) 63
cardiology (62) 62
platelet aggregation inhibitors - therapeutic use (62) 62
unstable angina (62) 62
management (61) 61
clopidogrel (60) 60
follow-up studies (60) 60
cardiac patients (59) 59
hemorrhage - chemically induced (56) 56
prospective studies (55) 55
stroke - prevention & control (55) 55
therapy (52) 52
ticlopidine - analogs & derivatives (52) 52
acute coronary syndrome (51) 51
adult (51) 51
outcomes (51) 51
drug therapy, combination (50) 50
aged, 80 and over (49) 49
patient outcomes (49) 49
patients (49) 49
percutaneous coronary intervention (49) 49
prevention (49) 49
myocardial infarction - therapy (48) 48
myocardial infarction - drug therapy (46) 46
research (45) 45
anticoagulants - therapeutic use (44) 44
atrial fibrillation - drug therapy (44) 44
warfarin (44) 44
acute coronary syndrome - mortality (43) 43
global registry (43) 43
heart attack (43) 43
angina pectoris (40) 40
clinical trials (40) 40
coronary vessels (40) 40
acute coronary syndrome - diagnosis (39) 39
acute coronary syndrome - drug therapy (38) 38
hospitalization (38) 38
health aspects (37) 37
analysis (36) 36
platelet aggregation inhibitors - administration & dosage (36) 36
anticoagulants - adverse effects (35) 35
platelet aggregation inhibitors - adverse effects (35) 35
stroke - etiology (35) 35
ticlopidine - therapeutic use (35) 35
cardiology and cardiovascular medicine (34) 34
cardiovascular diseases (34) 34
heart failure (34) 34
hospital mortality (34) 34
ischemia (34) 34
anticoagulants - administration & dosage (33) 33
atrial fibrillation - complications (33) 33
internal medicine (33) 33
aspirin - therapeutic use (32) 32
death (32) 32
myocardial infarction - diagnosis (32) 32
artery-disease (31) 31
dose-response relationship, drug (30) 30
events (30) 30
fibrinolytic agents - therapeutic use (30) 30
cardiac arrhythmia (28) 28
elevation myocardial-infarction (28) 28
retrospective studies (28) 28
risk stratification (28) 28
studies (28) 28
warfarin - administration & dosage (28) 28
bleeding (27) 27
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European cardiology, ISSN 1758-3756, 2016, Volume 11, Issue 1, pp. 60 - 61
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 2013, Volume 61, Issue 19, pp. 1998 - 2006
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 2017, Volume 69, Issue 22, pp. 2710 - 2720
Abstract Background For acute myocardial infarction (AMI) without heart failure (HF), it is unclear if β-blockers are associated with reduced mortality.... 
Cardiovascular | Internal Medicine | NSTEMI | preserved left ventricular systolic function | STEMI | average treatment effect | survival | propensity score | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | METOPROLOL | TRIAL | THERAPY | DISEASE | OUTCOMES | Heart Failure - complications | Myocardial Infarction - mortality | Prospective Studies | Survival Rate - trends | Follow-Up Studies | Ventricular Dysfunction - complications | Humans | Middle Aged | Ventricular Dysfunction - drug therapy | Male | Heart Failure - drug therapy | Dose-Response Relationship, Drug | Hospital Mortality - trends | Myocardial Infarction - complications | Propensity Score | Myocardial Infarction - drug therapy | Electrocardiography | Female | Registries | Aged | United Kingdom - epidemiology | Adrenergic beta-Antagonists - administration & dosage | Myocardial infarction | Heart attacks | Adjustment | Syngeneic grafts | Mortality | Cardiovascular disease | Coefficients | Patients | Survival | Beta blockers | Weighting | Ischemia | Risk assessment | Xenografts | Death | Fatalities | Infarction | Ventricle | Health risk assessment | Drug therapy | Heart diseases | PCI, percutaneous coronary intervention | CI, confidence interval | AMI, acute myocardial infarction | ATE, average treatment effect | STEMI, ST-segment elevation myocardial infarction | MINAP, Myocardial Ischaemia National Audit Project | LVSD, left ventricular systolic dysfunction | NSTEMI, non–ST-segment elevation myocardial infarction | HF, heart failure | Original Investigation
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 2007, Volume 49, Issue 19, pp. 1982 - 1988
Journal Article
The American heart journal, ISSN 0002-8703, 2015, Volume 170, Issue 4, pp. 675 - 682.e8
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2011, Volume 365, Issue 10, pp. 883 - 891
In this trial, 14,264 patients with atrial fibrillation were randomly assigned to receive either rivaroxaban or warfarin. In a per-protocol, as-treated... 
NON-INFERIORITY | ENOXAPARIN | MEDICINE, GENERAL & INTERNAL | DABIGATRAN | STROKE PREVENTION | PHARMACOKINETICS | EFFICACY | ANTITHROMBOTIC THERAPY | PHARMACODYNAMICS | THROMBOPROPHYLAXIS | ANTICOAGULATION | Thiophenes - therapeutic use | Thiophenes - adverse effects | Humans | Middle Aged | Warfarin - adverse effects | Male | Thiophenes - administration & dosage | Warfarin - administration & dosage | Warfarin - therapeutic use | Rivaroxaban | Aged, 80 and over | Female | Stroke - epidemiology | Embolism - epidemiology | Morpholines - adverse effects | Morpholines - therapeutic use | Stroke - prevention & control | Embolism - prevention & control | Double-Blind Method | Administration, Oral | Atrial Fibrillation - drug therapy | Morpholines - administration & dosage | Atrial Fibrillation - complications | Anticoagulants - therapeutic use | Treatment Outcome | Anticoagulants - adverse effects | Intention to Treat Analysis | Aged | Hemorrhage - chemically induced | Stroke (Disease) | Warfarin | Atrial fibrillation | Patient outcomes | Dosage and administration | Drug therapy | Comparative analysis | Risk factors | Fees & charges | Cardiac arrhythmia | Stroke | Heart attacks | Research & development--R&D | Embolisms | Equity | Equity stake | Hemorrhage | Bleeding | Embolism | Studies | Prevention | Fibrillation | Motivation | Ischemia | Thromboembolism | Drug dosages | Pharmaceuticals | Anticoagulants | Morpholines | Life Sciences | Thiophenes | Atrial Fibrillation
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2012, Volume 366, Issue 1, pp. 9 - 19
Journal Article